Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(4):438–444. doi: 10.1038/bjc.1997.407

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.

S A Butler 1, P J Wood 1, S Cole 1, C Williams 1, G E Adams 1, I J Stratford 1
PMCID: PMC2227976  PMID: 9275019

Abstract

Nitro-L-arginine inhibits the production of nitric oxide and can thereby cause vasoconstriction in vivo. One consequence of this is that nitro-L-arginine can increase hypoxia in a range of transplantable and spontaneous murine solid tumours. Bioreductive drugs such as RB6145 are more active under hypoxic conditions, and the combination of RB6145 with nitro-L-arginine in vivo shows greater anti-tumour activity than either agent individually. In mice given nitro-L-arginine at 10 mg kg(-1) i.p. up to 1 h before or after 300 mg kg(-1) i.p. RB6145, survival of KHT tumour cells was reduced by 3-4 logs when assessed by clonogenic assay 24 h after treatment. RB6145 or nitro-L-arginine alone caused no more than 20% cell kill. Similar effects were found in SCCVII tumours. The tumour response to the drug combination was tumour size dependent, with increased tumour cell sensitivity occurring when the tumour volume at the time of treatment was increased. Further, the response of KHT tumours to the combination of RB6145 and nitro-L-arginine was also dependent on the time interval between treatment and on when tumours were excised for determination of survival in vitro. The relative surviving fraction was about 0.3 for intervals less than 4 h but was reduced to 0.01 at 12 h and 0.001 at 24 h. These results were supported by histological examination of tumours, when necrosis at 2 h after treatment was less than 5% but increased to greater than 90% at 24 h. RB6145-induced normal tissue damage, as measured by CFU-A survival, was not altered by combining with nitro-L-arginine. Hence, this drug combination may provide therapeutic benefit. It is likely that the substantial anti-tumour effects are due to enhancement of bioreductive toxicity through increased tumour hypoxia, although additional mechanism(s) may also contribute to the overall response.

Full text

PDF
438

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrade S. P., Hart I. R., Piper P. J. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol. 1992 Dec;107(4):1092–1095. doi: 10.1111/j.1476-5381.1992.tb13412.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Austin P. E., McCulloch E. A., Till J. E. Characterization of the factor in L-cell conditioned medium capable of stimulating colony formation by mouse marrow cells in culture. J Cell Physiol. 1971 Apr;77(2):121–134. doi: 10.1002/jcp.1040770202. [DOI] [PubMed] [Google Scholar]
  3. Binger M., Workman P. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069). Cancer Chemother Pharmacol. 1991;29(1):37–47. doi: 10.1007/BF00686334. [DOI] [PubMed] [Google Scholar]
  4. Bremner J. C. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev. 1993 Jun;12(2):177–193. doi: 10.1007/BF00689809. [DOI] [PubMed] [Google Scholar]
  5. Bremner J. C., Stratford I. J., Bowler J., Adams G. E. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer. 1990 May;61(5):717–721. doi: 10.1038/bjc.1990.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brown J. M. Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo. Radiat Res. 1977 Dec;72(3):469–486. [PubMed] [Google Scholar]
  7. Brown J. M., Yu N. Y., Cory M. J., Bicknell R. B., Taylor D. L. In vivo evaluation of the radiosensitizing and cytotoxic properties of newly synthesized electron-affinic drugs. Br J Cancer Suppl. 1978 Jun;3:206–211. [PMC free article] [PubMed] [Google Scholar]
  8. Castellino S. M., Friedman H. S., Elion G. B., Ong E. T., Marcelli S. L., Page R., Bigner D. D., Dewhirst M. W. Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. Br J Cancer. 1995 Jun;71(6):1181–1187. doi: 10.1038/bjc.1995.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chaplin D. J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579–585. doi: 10.1016/0360-3016(87)90075-7. [DOI] [PubMed] [Google Scholar]
  10. Chaplin D. J. Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy. J Natl Cancer Inst. 1989 Apr 19;81(8):618–622. doi: 10.1093/jnci/81.8.618. [DOI] [PubMed] [Google Scholar]
  11. Chaplin D. J. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT). Br J Cancer. 1986 Nov;54(5):727–731. doi: 10.1038/bjc.1986.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cobbs C. S., Brenman J. E., Aldape K. D., Bredt D. S., Israel M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995 Feb 15;55(4):727–730. [PubMed] [Google Scholar]
  13. Cole S., Stratford I. J., Bowler J., Nolan J., Wright E. G., Lorimore S. A., Adams G. E. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):387–395. doi: 10.1016/0360-3016(91)90787-5. [DOI] [PubMed] [Google Scholar]
  14. Cole S., Stratford I. J., Fielden E. M., Adams G. E., Leopold W., Elliott W., Suto M., Sebolt-Leopold J. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908. Int J Radiat Oncol Biol Phys. 1992;22(3):545–548. doi: 10.1016/0360-3016(92)90872-f. [DOI] [PubMed] [Google Scholar]
  15. Edwards H. S., Bremner J. C., Stratford I. J. Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid. Int J Radiat Biol. 1991 Feb;59(2):419–432. doi: 10.1080/09553009114550381. [DOI] [PubMed] [Google Scholar]
  16. Hill S. A., Lonergan S. J., Denekamp J., Chaplin D. J. The effect of vinca alkaloids on tumour blood flow. Adv Exp Med Biol. 1994;345:417–422. doi: 10.1007/978-1-4615-2468-7_55. [DOI] [PubMed] [Google Scholar]
  17. Hill S. A., Sampson L. E., Chaplin D. J. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer. 1995 Sep 27;63(1):119–123. doi: 10.1002/ijc.2910630121. [DOI] [PubMed] [Google Scholar]
  18. Jenkins T. C., Naylor M. A., O'Neill P., Threadgill M. D., Cole S., Stratford I. J., Adams G. E., Fielden E. M., Suto M. J., Stier M. A. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem. 1990 Sep;33(9):2603–2610. doi: 10.1021/jm00171a040. [DOI] [PubMed] [Google Scholar]
  19. Kruuv J. A., Inch W. R., McCredie J. A. Blood flow and oxygenation of tumors in mice. II. Effects of vasodilator drugs. Cancer. 1967 Jan;20(1):60–65. doi: 10.1002/1097-0142(1967)20:1<60::aid-cncr2820200109>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  20. Meyer R. E., Shan S., DeAngelo J., Dodge R. K., Bonaventura J., Ong E. T., Dewhirst M. W. Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br J Cancer. 1995 Jun;71(6):1169–1174. doi: 10.1038/bjc.1995.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
  22. Moulder J. E., Dutreix J., Rockwell S., Siemann D. W. Applicability of animal tumor data to cancer therapy in humans. Int J Radiat Oncol Biol Phys. 1988 May;14(5):913–927. doi: 10.1016/0360-3016(88)90014-4. [DOI] [PubMed] [Google Scholar]
  23. Naylor M. A., Threadgill M. D., Showalter H. D., Stratford I. J., Stephens M. A., Fielden E. M., Adams G. E. Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro. Drug Des Discov. 1993;10(3):249–255. [PubMed] [Google Scholar]
  24. Pluznik D. H., Sachs L. The cloning of normal "mast" cells in tissue culture. J Cell Physiol. 1965 Dec;66(3):319–324. doi: 10.1002/jcp.1030660309. [DOI] [PubMed] [Google Scholar]
  25. Sheldon P. W., Hill S. A. Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumour in mice. Br J Cancer. 1977 Jun;35(6):795–808. doi: 10.1038/bjc.1977.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stratford I. J., Adams G. E., Bremner J. C., Cole S., Edwards H. S., Robertson N., Wood P. J. Manipulation and exploitation of the tumour environment for therapeutic benefit. Int J Radiat Biol. 1994 Jan;65(1):85–94. doi: 10.1080/09553009414550121. [DOI] [PubMed] [Google Scholar]
  27. Stratford I. J., Adams G. E., Godden J., Howells N. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo. Int J Radiat Biol. 1989 Mar;55(3):411–422. doi: 10.1080/09553008914550451. [DOI] [PubMed] [Google Scholar]
  28. Stratford I. J., Adams G. E., Godden J., Nolan J., Howells N., Timpson N. Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine. Br J Cancer. 1988 Aug;58(2):122–127. doi: 10.1038/bjc.1988.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Thomsen L. L., Lawton F. G., Knowles R. G., Beesley J. E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994 Mar 1;54(5):1352–1354. [PubMed] [Google Scholar]
  30. Thomsen L. L., Miles D. W., Happerfield L., Bobrow L. G., Knowles R. G., Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995 Jul;72(1):41–44. doi: 10.1038/bjc.1995.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thomson J. E., Rauth A. M. An in vitro assay to measure the viability of KHT tumor cells not previously exposed to culture conditions. Radiat Res. 1974 May;58(2):262–276. [PubMed] [Google Scholar]
  32. Tozer G. M., Prise V. E., Bell K. M. The influence of nitric oxide on tumour vascular tone. Acta Oncol. 1995;34(3):373–377. doi: 10.3109/02841869509093992. [DOI] [PubMed] [Google Scholar]
  33. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  34. Veszelovszky E., Thomsen L. L., Li Z., Baguley B. C. Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis. Eur J Cancer. 1993;29A(3):404–408. doi: 10.1016/0959-8049(93)90396-w. [DOI] [PubMed] [Google Scholar]
  35. Walton M. I., Workman P. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. Cancer Chemother Pharmacol. 1988;22(4):275–281. doi: 10.1007/BF00254231. [DOI] [PubMed] [Google Scholar]
  36. Wood P. J., Sansom J. M., Butler S. A., Stratford I. J., Cole S. M., Szabo C., Thiemermann C., Adams G. E. Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine. Cancer Res. 1994 Dec 15;54(24):6458–6463. [PubMed] [Google Scholar]
  37. Wood P. J., Sansom J. M., Stratford I. J., Adams G. E., Szabo C., Thiemermann C., Vane J. R. Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginine. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):443–447. doi: 10.1016/0360-3016(94)90435-9. [DOI] [PubMed] [Google Scholar]
  38. Wood P. J., Stratford I. J., Adams G. E., Szabo C., Thiemermann C., Vane J. R. Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem Biophys Res Commun. 1993 Apr 30;192(2):505–510. doi: 10.1006/bbrc.1993.1444. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES